(OSIS) OSI Systems - Overview
Stock: Scanner, Monitor, Sensor, Electronics, Manufacturing
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 44.2% |
| Relative Tail Risk | -7.78% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.77 |
| Alpha | 15.26 |
| Character TTM | |
|---|---|
| Beta | 1.179 |
| Beta Downside | 0.918 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.72% |
| CAGR/Max DD | 1.80 |
Description: OSIS OSI Systems January 12, 2026
OSI Systems (NASDAQ:OSIS) designs and manufactures electronic systems across three core segments-Security, Healthcare, and Optoelectronics & Manufacturing-serving customers in aviation, defense, medical, and industrial markets. Its product portfolio includes Rapiscan baggage and cargo scanners, Spacelabs patient-monitoring devices, and OSI Optoelectronics laser-diode and photon-based components, complemented by turnkey installation, training, and technical-support services.
According to the FY 2023 Form 10-K, OSI reported total revenue of approximately $1.23 billion, with the Security segment contributing ~55 % of sales and posting a 7.2 % operating margin, while Healthcare generated ~30 % of revenue with a 5.8 % margin. The company’s backlog at year-end stood at roughly $210 million, indicating near-term demand visibility. (Assumption: FY 2023 figures remain representative; FY 2024 guidance has not been publicly disclosed.)
Key macro drivers include the rebound in global air travel, which fuels demand for Rapiscan screening solutions, and sustained U.S. defense appropriations that support optoelectronic and laser-diode contracts. In healthcare, the shift toward remote patient monitoring and value-based care models is expanding the market for Spacelabs’ connected-care platforms. (Uncertainty: the pace of travel recovery and defense budget allocations could materially affect segment growth.)
For a deeper quantitative breakdown of OSIS’s valuation metrics, the ValueRay platform offers a free, data-rich snapshot worth checking out.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 153.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 9.78 > 1.0 |
| NWC/Revenue: 64.04% < 20% (prev 39.08%; Δ 24.96% < -1%) |
| CFO/TA 0.06 > 3% & CFO 161.5m > Net Income 153.1m |
| Net Debt (-331.7m) to EBITDA (262.5m): -1.26 < 3 |
| Current Ratio: 3.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.5m) vs 12m ago 2.52% < -2% |
| Gross Margin: 33.00% > 18% (prev 0.34%; Δ 3266 % > 0.5%) |
| Asset Turnover: 77.28% > 50% (prev 74.56%; Δ 2.72% > 0%) |
| Interest Coverage Ratio: 6.50 > 6 (EBITDA TTM 262.5m / Interest Expense TTM 34.0m) |
Altman Z'' 5.28
| A: 0.46 (Total Current Assets 1.69b - Total Current Liabilities 535.4m) / Total Assets 2.52b |
| B: 0.34 (Retained Earnings 862.0m / Total Assets 2.52b) |
| C: 0.10 (EBIT TTM 221.1m / Avg Total Assets 2.33b) |
| D: 0.50 (Book Value of Equity 845.5m / Total Liabilities 1.68b) |
| Altman-Z'' Score: 5.28 = AAA |
Beneish M -2.94
| DSRI: 1.05 (Receivables 833.2m/703.9m, Revenue 1.80b/1.59b) |
| GMI: 1.04 (GM 33.00% / 34.27%) |
| AQI: 0.88 (AQ_t 0.28 / AQ_t-1 0.32) |
| SGI: 1.13 (Revenue 1.80b / 1.59b) |
| TATA: -0.00 (NI 153.1m - CFO 161.5m) / TA 2.52b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of OSIS shares?
Over the past week, the price has changed by +8.44%, over one month by -4.68%, over three months by -3.90% and over the past year by +31.65%.
Is OSIS a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the OSIS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 298.8 | 10.2% |
| Analysts Target Price | 298.8 | 10.2% |
| ValueRay Target Price | 367.7 | 35.6% |
OSIS Fundamental Data Overview February 02, 2026
P/E Forward = 24.0385
P/S = 2.2917
P/B = 4.8734
P/EG = 2.0014
Revenue TTM = 1.80b USD
EBIT TTM = 221.1m USD
EBITDA TTM = 262.5m USD
Long Term Debt = 998.9m USD (from longTermDebt, last quarter)
Short Term Debt = 5.05m USD (from shortTermDebt, last quarter)
Debt = 5.05m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -331.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.79b USD (4.12b + Debt 5.05m - CCE 336.7m)
Interest Coverage Ratio = 6.50 (Ebit TTM 221.1m / Interest Expense TTM 34.0m)
EV/FCF = 26.62x (Enterprise Value 3.79b / FCF TTM 142.3m)
FCF Yield = 3.76% (FCF TTM 142.3m / Enterprise Value 3.79b)
FCF Margin = 7.92% (FCF TTM 142.3m / Revenue TTM 1.80b)
Net Margin = 8.52% (Net Income TTM 153.1m / Revenue TTM 1.80b)
Gross Margin = 33.00% ((Revenue TTM 1.80b - Cost of Revenue TTM 1.20b) / Revenue TTM)
Gross Margin QoQ = 32.67% (prev 32.03%)
Tobins Q-Ratio = 1.50 (Enterprise Value 3.79b / Total Assets 2.52b)
Interest Expense / Debt = 212.1% (Interest Expense 10.7m / Debt 5.05m)
Taxrate = 19.51% (9.38m / 48.1m)
NOPAT = 178.0m (EBIT 221.1m * (1 - 19.51%))
Current Ratio = 3.15 (Total Current Assets 1.69b / Total Current Liabilities 535.4m)
Debt / Equity = 0.01 (Debt 5.05m / totalStockholderEquity, last quarter 845.5m)
Debt / EBITDA = -1.26 (Net Debt -331.7m / EBITDA 262.5m)
Debt / FCF = -2.33 (Net Debt -331.7m / FCF TTM 142.3m)
Total Stockholder Equity = 905.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.58% (Net Income 153.1m / Total Assets 2.52b)
RoE = 16.91% (Net Income TTM 153.1m / Total Stockholder Equity 905.5m)
RoCE = 11.61% (EBIT 221.1m / Capital Employed (Equity 905.5m + L.T.Debt 998.9m))
RoIC = 10.79% (NOPAT 178.0m / Invested Capital 1.65b)
WACC = 10.25% (E(4.12b)/V(4.13b) * Re(10.26%) + (debt cost/tax rate unavailable))
Discount Rate = 10.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.48%
[DCF Debug] Terminal Value 60.82% ; FCFF base≈142.3m ; Y1≈93.4m ; Y5≈42.6m
Fair Price DCF = 56.72 (EV 602.7m - Net Debt -331.7m = Equity 934.4m / Shares 16.5m; r=10.25% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: 47.49 | EPS CAGR: 17.04% | SUE: 0.22 | # QB: 0
Revenue Correlation: 71.70 | Revenue CAGR: 13.31% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.56 | Chg30d=-0.300 | Revisions Net=+5 | Analysts=5
EPS current Year (2026-06-30): EPS=10.47 | Chg30d=+0.051 | Revisions Net=+4 | Growth EPS=+11.8% | Growth Revenue=+7.7%
EPS next Year (2027-06-30): EPS=11.51 | Chg30d=+0.119 | Revisions Net=+5 | Growth EPS=+10.0% | Growth Revenue=+5.5%